Data as of Nov 26
| +0.04 / +0.45%|
The 6 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 12.75, with a high estimate of 14.00 and a low estimate of 9.00. The median estimate represents a +42.62% increase from the last price of 8.94.
The current consensus among 6 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.